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The Present State of Coronary
Computed Tomography Angiography
A Process in Evolution
James K. Min, MD,* Leslee J. Shaw, PHD,† Daniel S. Berman, MD‡
New York, New York; Atlanta, Georgia; and Los Angeles, California
In the past 5 years since the introduction of 64-detector row cardiac computed tomography angiography (CCTA),
there has been an exponential growth in the quantity of scientific evidence to support the feasibility of its use in
the clinical evaluation of individuals with suspected coronary artery disease (CAD). Since then, there has been
considerable debate as to where CCTA precisely fits in the algorithm of evaluation of individuals with suspected
CAD. Proponents of CCTA contend that the quality and scope of the available evidence to date support the re-
placement of conventional methods of CAD evaluation by CCTA, whereas critics assert that clinical use of CCTA
is not yet adequately proven and should be restricted, if used at all. Coincident with the scientific debate under-
lying the clinical utility of CCTA, there has developed a perception by many that the rate of growth in cardiac im-
aging is disproportionately high and unsustainable. In this respect, all noninvasive imaging modalities and, in
particular, more newly introduced ones, have undergone a higher level of scrutiny for demonstration of clinical
and economic effectiveness. We herein describe the latest available published evidence supporting the potential
clinical and cost efficiency of CCTA, drawing attention not only to the significance but also the limitations of such
studies. These points may trigger discussion as to what future studies will be both necessary and feasible for
determining the exact role of CCTA in the workup of patients with suspected CAD. (J Am Coll Cardiol 2010;55:
957–65) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.087t
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iardiac computed tomography angiography (CCTA) has
merged in recent years as a promising noninvasive ana-
omic imaging modality for coronary artery and cardiac
tructural and functional evaluation (1). Developments in
omputed tomography (CT) technology, driven principally
y improvements in temporal resolution, spatial resolution,
nd volume coverage, now permit routine evaluation of the
oronary arteries and cardiovascular structures with clarity.
CTA has experienced resultant rapid clinical adoption by
ome for assessment of patients with suspected coronary
rtery disease (CAD). This year, scientific guidelines for
erformance, interpretation, and reporting of CCTA were
ublished that can aid the clinician-imager in the proper
xecution of CCTA. Nevertheless, despite the rapid growth
n the scientific evidence base that has supported the
ormation of these guidelines, numerous evidence gaps
ontinue to exist in this still nascent field, thus precluding
rom the *Department of Medicine and Radiology, Weill Medical College of Cornell
niversity, The New York Presbyterian Hospital, New York, New York; †Emory
niversity School of Medicine, Atlanta, Georgia; and the ‡Cedars-Sinai Medical
enter, Los Angeles, California. Dr. Min is on the Speakers’ Bureau of GE
ealthcare, and has received research support from GE Healthcare and Vital Images.
r. Berman has received grant support from GE Healthcare.w
Manuscript received May 14, 2009; revised manuscript received July 29, 2009,
ccepted August 4, 2009.he development of practice guidelines that can endorse the
roper clinical application of CCTA.
The purpose of this review is to highlight contemporary
evelopments that have occurred in the field of CCTA that
ay help to bridge certain evidence gaps. We focus our
iscussion on issues related to diagnostic accuracy, prognos-
ic risk stratification, cost-effectiveness, and safety.
iagnostic Coronary Artery Evaluation by CCTA
iagnostic accuracy of CCTA for obstructive CAD.
ince the introduction of 64-detector row CCTA in 2005,
50 studies have been published that compared the diag-
ostic performance of CCTA with that of invasive coronary
ngiography (ICA) as the reference standard. Several pooled
nalyses have been performed that showed the diagnostic
erformance of 64-detector row CCTA, with high per-
atient sensitivity and specificity ranging from 91% to 99%
nd 74% to 96%, respectively (2–6). These early studies
ere uniformly retrospective in design and limited to single
enters, thus possessing numerous limitations including
eferral bias (patients already being referred for ICA),
pectrum bias (patients had a high pretest CAD likelihood
nd did not represent those for whom noninvasive imaging
s generally performed), workup bias (overlooking patients
ho may have otherwise been found to have false-negative
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Present State of CCTA March 9, 2010:957–65findings), ascertainment bias (us-
ing nonrandom samples resulting
in altered results), and publica-
tion bias (emphasizing only pos-
itive results). To address many of
these limitations, 3 prospective
multicenter studies were recently
reported that detail the diagnos-
tic performance of CCTA in dif-
ferent populations (Table 1).
The purpose of these studies
was to define the concordance
between CCTA and a reference
standard of ICA, and, thus, each
of these studies was limited to
patients being clinically referred
for ICA. The first of these trials
was the ACCURACY (Assess-
ment by Coronary Computed
omographic Angiography of Individuals Undergoing In-
asive Coronary Angiography) trial, a 16-center U.S.-based
tudy that restricted analysis to patients without known
AD undergoing CCTA before elective ICA (7). Reasons
or ICA referral included stable chest pain syndrome and/or
bnormal functional stress testing results. Among the 230
ubjects, only 13.9% were found to have obstructive CAD at
he 70% stenosis threshold by quantitative coronary an-
iography. Although the prevalence of CAD in the AC-
URACY trial cohort highlighted the imperfections of
urrent clinical and imaging algorithms for the proper
dentification of individuals with obstructive CAD, it nev-
rtheless permitted an assessment of CCTA diagnostic
erformance in a patient population for whom CCTA use is
enerally advocated. The diagnostic sensitivity, specificity,
nd positive predictive value (PPV) and negative predictive
alue (NPV) of CCTA to detect a 70% stenosis in this
opulation were 94%, 83%, 48%, and 99%, respectively.
mportantly, these test characteristics were calculated re-
orting all vessel segments, without exclusion of patients for
aseline heart rate, coronary artery calcium score (CACS),
r body mass index; which is in contrast to many previous
ingle-center studies that reported higher diagnostic perfor-
ance characteristics. The area under the receiver-operator
haracteristic curve, which describes the discriminatory
ower of diagnostic testing across a wide range of cutoff
alues, for identification of patients with70% stenosis was
.95, thereby definitively establishing the high diagnostic
ummary of Diagnostic Performance of 64-Detector Row CCTA FroTable 1 Summary of Diagnostic Performance of 64-Detector Ro
n CAD Prevalence
Pa
Stable Unstable
ACCURACY (7) 230 25% X
CORE64 (8) 291 56% X
Meijboom et al. (9) 360 68% X X
Abbreviations
and Acronyms
CAD  coronary artery
disease
CACS  coronary artery
calcium score(s)
CCTA  cardiac computed
tomography angiography
CT  computed
tomography
ICA  invasive coronary
angiography
MPS  myocardial
perfusion scintigraphy
NPV  negative predictive
value
PPV  positive predictive
valueAD  coronary artery disease; CCTA  cardiac computed tomography angiography; NPV  negative preccuracy for both detection and exclusion of obstructive
oronary artery stenosis in individuals without known CAD
ith a low prevalence of CAD (Fig. 1).
In contrast, the 291 patients enrolled in the multicenter
ORE64 (Coronary Evaluation on 64) study, encompassed
n admixture of patients both with and without known
AD with baseline CACS 600 Agatston units (8). As
uch, the prevalence of obstructive CAD at the 50%
ntraluminal stenosis threshold was higher than that ob-
erved in the ACCURACY trial, with a prevalence of 56%
espite exclusion for elevated CACS of 600 Agatston
nits. In the CORE64 study, the per-patient sensitivity,
pecificity, PPV, and NPV were 85%, 90%, 91%, and 83%,
espectively. These findings are in accord with those of the
CCURACY trial because the higher prevalence of CAD
esulted in predictably lower NPVs and higher PPVs. In
his study population, the area under the curve was 0.91 for
CA-confirmed CAD and similar to ICA for the prediction
f subsequent coronary artery revascularization.
The most recent prospective multicenter study evaluated
60 patients without known CAD presenting with both
cute and stable chest pain (9). As expected, the CAD
revalence was high (68%), and diagnostic performance of
CTA revealed a per-patient sensitivity, specificity, PPV,
nd NPV of 99%, 64%, 86%, and 97%, respectively. In
onjunction with the ACCURACY trial, the high sensitiv-
ty and NPV in individuals without known CAD highlight
he ability of CCTA to detect and exclude obstructive
oronary artery stenosis across wide disease prevalences,
lbeit with comparatively low specificity and PPVs. The
atter of these diagnostic performance characteristics under-
cores an excessive rate of false-positive CCTA findings in
hich intraluminal stenosis severity by CCTA is errone-
usly overestimated. This fact necessitates careful consider-
tion when using CCTA because false-positive findings
ay precipitate unnecessary referral for ICA. Particularly in
he lower risk diagnostic population, this may result in the
erformance of layered noninvasive and invasive procedures
or individuals who may, in fact, not have needed any testing
t all.
iagnostic accuracy of CCTA for myocardial ischemia.
esults of functional myocardial perfusion scintigraphy
MPS) have proven robust for diagnosis, risk stratification,
nd guidance of treatment decision making (10–21). Both
arge prospective, observational registries and multicenter
andomized, controlled trials support a symptom benefit
nd potential risk reduction of revascularization for those
spective Multicenter StudiesTA From Prospective Multicenter Studies
Type
Sensitivity Specificity PPV NPVnown CAD Known CAD
X 95% 83% 64% 99%
X X 85% 90% 91% 83%
X 99% 64% 86% 97%m Prow CC
tient
No Kdictive value; PPV  positive predictive value.
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March 9, 2010:957–65 Present State of CCTAith moderate to severe ischemia (16,17,22). The converse
f this finding is also true; namely, among patients without
vident extensive myocardial ischemia by MPS, an adverse
AD prognosis is higher for patients undergoing coronary
evascularization than receiving medical therapy. As such,
here has been an effort to determine whether CAD stenosis
everity detection by CCTA successfully identifies individ-
als with myocardial ischemia.
In a prospective study of 78 patients undergoing sequen-
ial CCTA, MPS, and ICA, the sensitivity and NPV for
CTA to detect any perfusion defect was high (94%),
lthough the specificity and PPV were only 64% and 63%,
espectively (23). Given that increasing rates of false-
ositive results will reduce both specificity and PPV, these
ndings suggest an overestimation of CAD stenoses by
CTA. Interestingly, these findings did not reflect a failure
f CCTA per se to accurately assess coronary artery stenosis
Figure 1 CCTA Examples
(A) Cardiac computed tomography angiography (CCTA) of the right coronary artery
significant coronary artery plaque. (B) CCTA (left) and left anterior descending artery (ecause the probabilistic odds of CCTA to detect myocar- Cial ischemia were identical to those of ICA. Rather, an
xcessively high rate of false-positive results is seen by any
ethod of anatomic evaluation, thus questioning the rele-
ance of coronary artery stenosis detection by anatomic
ethods for identification of individuals who may most
enefit from revascularization. In a similar study of 79
atients undergoing CCTA and ICA with fractional flow
eserve measurements, comparable findings were observed.
lthough the sensitivity of CCTA by visual estimation to
etect lesions with a fractional flow reserve 0.75 was high
94%), the specificity to detect such lesions was poor (40%)
24). A quantitative CCTA-based method improved diag-
ostic accuracy but at the loss of sensitivity; these findings
ere similar to those observed for quantitative coronary
ngiography.
A similar theme emerges from pooled analyses of studies
pecifically examining the association between MPS and
nd left anterior descending artery (right), which demonstrates no
which demonstrates high-grade obstructive and mild plaque, respectively.(left) a
right),CTA findings (25). CCTA judged as revealing 50%
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Present State of CCTA March 9, 2010:957–65tenosis at the per-patient level generally portends a normal
PS, in keeping with the high NPV of CCTA. Con-
ersely, however, CCTA noted to reveal 50% stenosis is
ssociated with abnormal MPS only approximately half of
he time (Fig. 2) (26). Collectively, these findings demon-
trate that anatomic measures of stenosis severity and
unctional measures of myocardial perfusion provide dis-
rete and potentially complementary information regarding
AD (i.e., anatomic detection of atherosclerosis and func-
ional detection of ischemia). When the criterion of 50%
r 70% stenosis has been used, a criterion now considered
o be a superior standard for hemodynamic significance and
uiding decisions regarding revascularization, higher PPVs
f CCTA regarding ischemia by MPS have been shown
27,28).
Nevertheless, although CCTA and MPS do provide
omplementary information, early studies suggested meth-
ds by which CCTA plaque identification may enhance
rediction of functional information, thereby lessening the
schemic gap between these 2 types of studies. Previous
valuations of CCTA relied primarily on binary measures of
oronary artery stenosis severity (i.e., 50% [or 70%]
tenosis). Recent CCTA studies extended this categoriza-
ion to a more comprehensive plaque assessment beyond
ntraluminal stenosis severity, including plaque location,
istribution, composition, and overall burden, to determine
hether these combined measures can augment the predic-
ion of myocardial ischemia.
Lin et al. (29) evaluated 163 patients undergoing both
4-detector row CCTA and MPS. In addition to binary
lassification of patients with or without obstructive CAD,
laque by CCTA at the per-patient level was also graded by
everal scores that aimed to describe overall coronary artery
laque burden, accounting for both plaque burden and
laque location. These scores were expressed as a segment
tenosis score, a segments-at-risk score, and a modified
Figure 2 Relationship Between CCTA and Ischemia
Predictive value by according to 5 studies of cardiac computed tomography
angiography (CCTA) to detect myocardial ischemia by myocardial perfusion scin-
tigraphy. Reprinted, with permission, from Hachamovitch et al. (26). NPV 
negative predictive value; PPV  positive predictive value.Cuke CAD score, respectively. Plaques at the per-patient
evel were also described by plaque composition scores,
hich tallied the numbers of coronary segments (based on a
odified 16-segment American Heart Association model)
xhibiting primarily noncalcified plaque (70% noncalci-
ed), mixed plaque (30% to 70% noncalcified), and calcified
laque (30% noncalcified).
In keeping with previous studies, CCTA identification of
bstructive CAD did not successfully identify individuals
ith abnormal MPS findings. However, measures of per-
atient coronary artery plaque burden, proximity, and loca-
ion, including the segment stenosis score, the segments-at-
isk score, and the modified Duke CAD score, were
redictive of identifying individuals with abnormal MPS
ndings. Increasing numbers of segments exhibiting mixed
laque similarly identified individuals with abnormal MPS
ndings. An extension of these findings was observed in a
tudy of 165 patients undergoing treadmill exercise testing
n which the modified Duke CAD score by CCTA suc-
essfully identified individuals with increasing severity of
xercise-induced ST-segment depression as well as a de-
reasing Duke treadmill score (30). Notably, increasing
radations of CAD by CCTA from none to nonobstructive
o obstructive also predicted a stepwise reduction in overall
ruce treadmill protocol exercise times. Collectively, these
ndings suggest that comprehensive assessment of coronary
rtery plaque by CCTA, beyond binary categorization of
tenosis severity, may enhance the prediction of individuals
ith inducible myocardial ischemia.
isk stratification by CCTA in individuals with stable
hest pain. Of importance in the diagnostic performance
f any test is its prognostic potential. The robustness of
unctional stress testing, by electrocardiography or imaging,
o provide valuable information regarding risk stratification
n a diversity of patient types explains, in large part, its
opularity of use and critical importance in the evaluation of
atients with suspected CAD. In contrast to the wealth of
ata that support the clinical effectiveness of functional
tress testing, relatively few studies exist to support the
rognostic implications of CCTA. This is due to the recent
ntroduction of CT scanners capable of performing routine
CTA, which has limited the time required for accrual of
ardiac events after testing. Despite the multitude of plaque
haracteristics that are available for identification by CCTA,
arly work in this field has primarily focused on the
elationship of obstructive CAD to the incidence of adverse
AD prognosis.
An initial publication examined coronary artery stenosis
everity in relation to the incidence of all-cause death in
,127 patients undergoing CCTA by 16-detector row
CTA (31). At an intermediate-term follow-up of 15
onths, CCTA measures of CAD severity, extent, location,
nd distribution were independent predictors of the risk of
ll-cause mortality. Both moderate (50% to 69%) and
evere (70%) luminal diameter stenoses revealed by
CTA were associated with a higher mortality risk com-
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March 9, 2010:957–65 Present State of CCTAared with less obstructive plaques, and the risk of death
ncreased with numbers of major epicardial vessels affected.
CTA characteristics predicting a high risk of death from
modified Duke CAD score (listed by increasing risk)
ncluded: 1) 2 segments with moderate stenosis or 1
egment with severe stenosis; 2) 3 segments with moderate
tenosis, 2 segments with severe stenosis, or severe stenosis
n the proximal left anterior descending artery; 3) 3 seg-
ents with severe stenosis or 2 segments with severe
tenosis that included the proximal left anterior descending
rtery; and 4) moderate or severe left main artery stenosis,
ith a 15% 1.5-year mortality rate. Of equal importance,
CTA was able to accurately identify individuals with a low
ncidence of risk of all-cause mortality. Among 333 patients
ith no detectable coronary artery plaque by CCTA, the
nnualized death rate was 0.3%, suggesting the detection of
low-risk group.
Although long-term prognostic studies using current-
eneration CT scanners are as yet unavailable, studies using
lder generation scanners (including electron beam CCTA)
ave accumulated a longer accumulated experience of study.
n a recent analysis of 2,538 consecutive patients without
nown CAD undergoing electron beam CCTA followed
or 6.5 years for all-cause mortality, a higher mortality risk
as identified for individuals with greater numbers of major
picardial coronary artery vessels exhibiting obstructive
AD (32). In comparison with patients without CAD, the
ortality incidence increased 2- to 3-fold. Even among
ndividuals without evident obstructive CAD, the presence
f nonobstructive CAD in all 3 major coronary vessels
onferred a significantly increased risk of mortality. Impor-
antly, for patients without evident CAD, the annualized
ortality rate was 0.3% in this follow-up of nearly 7 years,
uggesting that the “warranty” period of a normal CCTA
ay be extensive. Furthermore, risk prediction by CT-
dentified plaque was independent of and additive to tradi-
ional CAD risk factor scoring and CACS.
CCTA has also been evaluated for its ability to identify
ndividuals at risk of other major adverse cardiovascular
vents. In the largest of these studies, 1,256 patients
ndergoing 64-detector row CCTA were studied for all-
ause death in relation to CAD severity. Individuals with
bstructive CAD experienced significantly higher rates of
evere major adverse cardiovascular events (odds ratio: 17.3,
5% confidence interval [CI]: 3.6 to 82.5, p  0.001), as
efined as cardiac death, myocardial infarction, or unstable
ngina requiring hospitalization. Conversely, those individ-
als without obstructive CAD by CCTA experienced major
dverse cardiovascular events at a substantially lower rate
han would have been predicted by traditional Framingham
isk factor scoring.
Pooled analyses of studies of individuals undergoing
CTA indicate an inordinately high annualized event rate
11.1%, 95% CI: 5.1% to 2.5%) for those with obstructive
AD, which is by and large higher than that observed forndividuals with abnormal perfusion shown by MPS (6.2%, h5% CI: 5.9% to 6.5%) or inducible wall motion abnormal-
ties by stress echocardiography (7.5%, 95% CI: 5% to
3.4%), albeit with overlapping CIs (33,34). These obser-
ations have prompted the question as to the relative
rognostic risk stratification proffered by CCTA compared
ith functional stress testing. Further, whether CCTA
laque characteristics predict future adverse CAD outcomes
n a manner that is equivalent to or synergistic with that of
erfusion or wall motion findings has also been raised. To
ate, only 2 studies have been performed to offer early data
ith respect to these issues.
In the first of these studies, individuals undergoing
CTA for CAD evaluation (n  1,132) were compared
ith propensity score–matched outpatients (n  7,849)
eferred for MPS, for a primary end point of all-cause death
35). Similar 2-year survival rates after CCTA and MPS
ere noted (97% for both). In a comparison of CCTA
ndings as graded by a modified Duke CAD index versus
he percentage of ischemic myocardium by single-photon
mission CT, the annual mortality rates predicted by
CTA were directly proportional to the percentage of
schemic myocardium by MPS, ranging from 0.2% to 11%
or CCTA and from 0% to 12% for MPS. These findings
uggest that the prognostic potential of CCTA is similar to
hat of perfusion testing. Although the range of values for
ow to high risk was similar, a more gradual increase in risk
as noted for CCTA in patients with less extensive CAD.
ecause CCTA is capable of identifying nonobstructive
AD for which functional MPS findings may be expected
o be normal, future prospective studies are necessary to
xamine the relationship of nonobstructive plaque identifi-
ation to adverse CAD events for further refinement of risk
ssessment on the lower ends of the risk spectrum.
A more recent study of 541 patients prospectively under-
oing both CCTA and MPS examined the relative prog-
ostic potential of CCTA CAD detection and MPS per-
usion abnormalities in individuals with suspected CAD
36). During a 2-year follow-up, annualized mortality and
onfatal myocardial infarction rates were higher for patients
ith obstructive CAD compared with patients with none or
ild CAD (4.8% and 1.8%, respectively), findings similar
or patients with abnormal versus normal myocardial per-
usion (3.8% vs. 1.1%, respectively). Survival analyses dem-
nstrated comparable risk stratification for anatomic CAD
ndings by CCTA and functional perfusion by MPS.
natomic and functional measures were synergistic for the
rediction of death or myocardial infarction. In addition,
laque composition seemed to be important for predicting
utcomes because individuals with 2 noncalcified plaques,
3 mixed plaques, and 4 calcified plaques experienced
igher rates of death and MI than those with none.
These proof-of-principle studies will require corrobora-
ion in other centers and in different patient cohorts.
urther, direct comparison of CCTA with MPS for prog-
ostic risk stratification in individuals undergoing either test
as to date not been performed. Before CCTA is widely
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Present State of CCTA March 9, 2010:957–65ccepted as possessing equivalent or superior abilities for
isk stratification, head-to-head evaluations will likely be
equired using randomized, controlled trials, several of
hich have been proposed but not yet initiated.
se of CCTA in the evaluation of acute chest pain. Al-
ost 6 million individuals are evaluated each year for acute
hest pain in the emergency department (34). Despite
tandardized protocols and high vigilance, between 2% and
% of patients are erroneously discharged with missed
yocardial infarction (37). Proponents of CCTA advocate
ts potential usefulness in this patient subgroup, highlight-
ng the NPV of CCTA to successfully identify individuals
n whom no obstructive CAD exists and who have a
avorable prognosis.
A single-center, randomized study of 197 individuals
resenting with acute chest pain to the emergency depart-
ent compared a CCTA-based diagnostic evaluation strat-
gy with standard-of-care algorithms that used MPS (38).
n contrast to individuals undergoing standard-of-care as-
essment, individuals undergoing CCTA experienced re-
uced diagnostic time in the emergency department (3.4
nd 15.0 h, respectively; p  0.01) and fewer repeat
valuations for chest pain. These findings translated to
ower costs for a CCTA-based evaluation by almost $300
er patient. In 6-month and 2-year follow-up, no adverse
AD events occurred in discharged individuals by either a
CTA- or standard-of-care–based evaluation (G. Raff,
ersonal communication, June 2009).
In a related study, 368 patients presenting to the emer-
ency department with acute chest pain underwent 64-slice
CTA after initially negative findings on troponin mea-
urements and electrocardiograms (39). The caring physi-
ian was blinded to the CCTA results. One half of the study
atients had no evidence of CAD by CCTA, with an NPV
f 100% for acute coronary syndrome in a 6-month follow-
p. By contrast, the presence of any plaque by CCTA had
00% sensitivity for acute coronary syndrome detection,
lthough the specificity for acute coronary syndrome detec-
ion was low (54%). Specificity for acute coronary syndrome
etection was improved by restriction of CAD to those with
50% stenosis by CCTA, findings, which were incremental
o thrombolysis in myocardial infarction risk scores.
In aggregate, the current data on CCTA for acute chest
ain suggest that in appropriate populations, CCTA may be
seful as a successful triage tool that may allow safe early
ischarge of low-risk patients. On the other hand, the
resence of nonobstructive coronary artery plaque portends
low but nonzero risk, congruent with the data observed in
he stable chest pain population, and is therefore an imper-
ect stand-alone instrument for triaging individuals with
ossible acute coronary syndrome. Although these early data
re favorable, further study is still needed in larger cohorts to
erify the safety and effectiveness of a CCTA-based evalu-
tion of acute chest pain patients.
ost-efficiency and resource utilization after CCTA. At
resent, the potential clinical utility of CCTA is not iniformly recognized by third-party payers, with private
ayer coverage of CCTA for CAD evaluation existing in
pproximately 50% of U.S. plans. Concerns of unchecked
rowth for CCTA have also been expressed by the Centers
or Medicare and Medicaid Services in a proposed National
overage Determination for CCTA that called for the
nswer to 3 questions to appraise the value of CCTA (40).
hese 3 questions, which deal with diagnostic test accuracy,
esource utilization, and improvement in patient-centered
ealth outcomes, were reinforced by the Medicare Evidence
evelopment and Coverage Advisory Committee, with
nput from the National Heart, Lung, and Blood Institute,
hich prioritized the need to answer the question: how
ost-effective is CCTA (41)?
Given the shorter clinical experience with CCTA com-
ared with other modalities such as MPS, relatively little
vidence is as yet available to describe the cost-effectiveness
f CCTA. Early evaluations of the economic implications
f a CCTA-based strategy have relied primarily on single-
enter “back-of-the-envelope” calculations of costs or deci-
ion analytic models whose findings are largely driven by
easures of test sensitivity and specificity.
One recent multicenter study related total health care and
AD-related costs to downstream CAD hospitalization
utpatient visits, acute myocardial infarction and new-onset
ngina in 8,235 matched low-risk individuals undergoing
CTA or MPS (42). In a 1-year follow-up, adjusted CAD
osts were 25.9% lower in individuals undergoing CCTA
ompared with MPS, by an average of $1,075 per patient.
hese differences were driven, in part, by the lower likeli-
ood of undergoing coronary revascularization. Despite
his, rates of myocardial infarction and CAD-related hos-
italization were similar, and rates of new-onset angina in
ndividuals undergoing CCTA were lower than those re-
orted for MPS. These findings were extended in a similar
tudy of 9,690 matched intermediate-risk individuals un-
ergoing CCTA or MPS (43). In a 9-month follow-up,
djusted total and CAD-related costs were one third lower
or individuals after CCTA compared with MPS by an
verage of $467 per patient. Rates of new CAD medications
nd coronary revascularization were similar in CCTA and
PS patients, and the cost differences were explained in
art due to methods of downstream testing. Individuals
valuated by CCTA were more likely to undergo follow-up
esting with MPS, whereas MPS individuals were more
ikely to undergo downstream testing by ICA. Despite
ower costs for CCTA, no differences were observed for
AD events, including CAD hospitalizations, CAD out-
atient visits, myocardial infarction, or new-onset angina.
Although these findings are provocative, they are far from
efinitive. The aforementioned studies used administrative
laims data, and, thus, clinical results of CCTA or MPS as
ell as symptom data are lacking. The deficiency of this
mportant clinical information prevents ascertainment of
hether the increased costs noted in the MPS group were,n fact, appropriate. In addition, the nonrandomized nature
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March 9, 2010:957–65 Present State of CCTAf the individuals undergoing CCTA or MPS, despite
areful statistical matching techniques, may be beset by
esidual confounders. Further, these analyses were per-
ormed using 2005 and 2006 claims data, at a time when
linical use of 64-detector row CCTA was in its inception.
he increased rates of ICA after MPS may simply reflect
he unavailability of CCTA to those patients at that time.
afety. Performance of CCTA results in non-negligible
oses of ionizing radiation, and this has been a criticism of
ts use. Traditional measures of radiation dosimetry by
lectrocardiogram-gated CCTA have used the use of an
verage conversion coefficient (0.014 mSv·mGy1·cm1) to
stimate the effective radiation dose from the scanner-
eported dose–length product; the millisievert (mSv) unit is
ypically used for doses (44). Although radiation doses from
PS, ICA, and nonelectrocardiogram-gated noncardiac
T are generally straightforward in their measurements, the
adiation dose of CCTA is highly variable and substantially
epends on the image acquisition parameters.
Among the numerous methods of performing CCTA,
adiation doses can vary by an order of magnitude, and in
ractice, these variations are similarly observed. In PRO-
ECTION I (Prospective Multicenter Study on Radiation
ose Estimates of Cardiac CT Angiography in Daily
ractice), 120 sites reported radiation dose estimates from
CTA (45). The average radiation dose conferred by
CTA was 12 mSv, or approximately 4 times that derived
rom the annual background radiation from radon. Al-
hough this dose compares favorably with MPS, it is
evertheless twice the amount of radiation associated with a
iagnostic ICA. Further, the variation of dose at sites
xperienced in performing CCTA in PROTECTION I
as wide, and ranged from 4 to nearly 30 mSv.
In an effort to minimize radiation dose from CCTA,
umerous methods for dose reduction have been developed.
hese include automated tube current modulation, electro-
ardiographic modulation, prospective axial triggering, re-
uced tube voltage, and iterative reconstruction techniques.
CTA-Related Issue and Pro and Con ArgumentTable 2 CCTA-Related Issue and Pro and Con Argument
CCTA Diagnostic Test
Characteristic Pro
Diagnosis of
obstructive CAD
CCTA possesses a high NPV for identification of ind
whom no further testing is warranted.
Anatomic diagnosis of
CAD
Most individuals undergoing imaging do not have s
CAD and, thus, a test with high NPV is most use
Detection of subclinical
atherosclerosis
CCTA diagnoses individuals with subclinical atheros
which offers the opportunity to initiate primary p
future CAD events.
Prognosis CCTA plaque characterization for prognostic risk as
as effective and is synergistic to stress imaging
Resource utilization CCTA can act as an effective gatekeeper to cardiac
catheterization, thereby reducing costs.
Safety CCTA exposes a patient to less radiation than other
including nuclear stress testing and invasive angAD  coronary artery disease; CCTA  cardiac computed tomography angiography; NPV  negative prehe combination of these techniques can result in more
han a 90% radiation dose reduction to 1 mSv (46).
evertheless, the penetration of these techniques into wide-
pread clinical practice outside of specialized centers has not
et occurred, and radiation dose associated with CCTA
emains excessively high. A recent multicenter, single-state
egistry, reflecting real-world practice, reported unaffected
oses of 25 mSv with CCTA (47). Educational interven-
ions to these sites reduced radiation by almost 50%,
uggesting that instruction and implementation of radiation
echniques can effectively lower the radiation dose and
otentially improve patient safety.
eneralizability. Although study of CCTA has been
bundant since the introduction of 64-detector row CCTA
canners in 2005, the generalized applicability of these
bservations remains to be seen. CCTA studies have, to
ate, been largely performed by centers with expertise in
mage acquisition, reconstruction, and interpretation. Fur-
her, studies of CCTA have generally limited inclusion of
atients for whom CCTA performance would be most
ikely successful. The ability of CCTA to be commonly
pplied in subjects with high CACS, irregular heart
hythms, or obese individuals can result in significant
rtifacts related to beam hardening, misregistration, and
mage noise, respectively. Whether CCTA can be rou-
inely performed in such subjects remains to be deter-
ined, but diagnostic performance will likely be less
obust than that previously reported for individuals with-
ut these characteristics.
onclusions
he Irish playwright George Bernard Shaw once wrote,
New opinions often appear first as jokes and fancies, then
s blasphemies and treason, then as questions open to
iscussion, and finally as established truths” (48). Primarily
ver the past 3 years, the profusion of scientific evidence
elated to CCTA has permitted evolution of the field to the
Con
ls in CCTA possesses high rates of false positive findings, which will lead
to unnecessary catheterization and revascularization.
nt Ischemia-guided management is more proven than anatomy-guided
management.
is,
ion of
Most individuals diagnosed by CCTA with subclinical atherosclerosis
should already be receiving medical therapy. Further CCTA
diagnosis may simply represent lead-time bias for which no
intervention is necessary or useful.
ent is
s.
Functional stress testing with or without imaging is robust for
risk stratification.
CCTA will simply serve as an add-on test rather than as a
stand-alone test, thereby increasing costs.
hy.
CCTA exposes a patient to excessive radiation.ividua
ignifica
ful.
cleros
revent
sessm
finding
tests,
iograpdictive value.
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Present State of CCTA March 9, 2010:957–65oint of raising questions, most of which remain open to
iscussion. In the past year alone, considerable discussion
ccurred regarding the widespread use of CCTA in the
valuation of patients with suspected CAD. Interestingly,
he same available evidence often evokes directly contrary
nterpretations from proponents and critics of CCTA
Table 2).
The reasons underlying this debate stem not only from
ifferences in scientific opinion, but also under a backdrop
f spiraling health care costs and disproportionate growth in
oninvasive imaging. In this regard, newly introduced
echnologies such as CCTA have experienced a “raising of
he bar” of medical evidence required to either prove or
isprove their clinical and economic effectiveness. Although
his standard of evidence development has not been a
istorical mandate for other imaging methods, it will never-
heless be required for CCTA in the current budget-neutral
ealth care environment that stresses comparative effective-
ess against established methods of CAD evaluation.
What, then, is the current and future state of CCTA? In
ur opinion, the diagnostic accuracy of CCTA has already
een definitively established. By well-performed prospec-
ive, multicenter studies, CCTA is an accurate diagnostic
odality with superior diagnostic accuracy to detect and
xclude anatomically obstructive CAD. The exclusion of
AD seems to offer immediate clinical usefulness and is
ikely to reduce the need for subsequent resource utilization.
owever, improvements are still necessary to reduce over-
stimation of CAD severity. With newer generation CT
canners, this will be a process of evolution.
Nevertheless, the ability of CCTA, beyond conventional
ethods of CAD evaluation, to predict patient-centered
utcomes and to invoke appropriate medical or invasive
reatment and do so safely and in a cost-effective manner has
et to be determined. The future of CCTA will lie in the
nswers to these questions, which will depend on the type of
igh-quality evidence typically only derived from large,
ell-designed, randomized, controlled trials.
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